{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:56:01Z","timestamp":1758815761264,"version":"3.37.0"},"reference-count":69,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,3,6]],"date-time":"2009-03-06T00:00:00Z","timestamp":1236297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction Biology"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The high prevalence of psychostimulant abuse observed in schizophrenic patients may be related to the development of mesolimbic dopaminergic supersensitivity (MDS) or nigrostriatal dopaminergic supersensitivity (NDS) in response to the chronic blockade of dopamine receptors produced by typical neuroleptic treatment. We compared the effects of withdrawal from long\u2010term administration of the typical neuroleptic haloperidol (Hal) and\/or the atypical agent risperidone (Ris) on MDS and NDS, behaviorally evaluated by amphetamine\u2010induced locomotor stimulation (AILS) and apomorphine\u2010induced stereotypy (AIS) in mice, respectively. We further evaluated the duration of MDS and investigated the specific role of dopamine D2 receptors in this phenomenon by administering the D2 agonist quinpirole (Quin) to mice withdrawn from long\u2010term treatment with these neuroleptics. Withdrawal (48 hours) from long\u2010term (20 days) Hal (0.5\u2003mg\/kg i.p.) (but not 0.5\u2003mg\/kg Ris i.p.) treatment potentiated both AILS and AIS. Ris co\u2010administration abolished the potentiation of AILS and AIS observed in Hal\u2010withdrawn mice. Ten days after withdrawal from long\u2010term treatment with Hal (but not with Ris or Ris\u2003+\u2003Hal), a potentiation in AILS was still observed. Only Hal\u2010withdrawn mice presented an attenuation of locomotor inhibition produced by Quin. Our data suggest that the atypical neuroleptic Ris has a pharmacological property that counteracts the compensatory MDS and NDS developed in response to the chronic blockade of dopamine receptors imposed by Ris itself or by typical neuroleptics such as Hal. They also indicate that MDS may be long lasting and suggest that an upregulation of dopamine D2 receptors in response to long\u2010term treatment with the typical neuroleptic is involved in this phenomenon.<\/jats:p>","DOI":"10.1111\/j.1369-1600.2008.00145.x","type":"journal-article","created":{"date-parts":[[2009,3,6]],"date-time":"2009-03-06T12:04:19Z","timestamp":1236341059000},"page":"283-293","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["PRECLINICAL STUDY: Long\u2010term haloperidol treatment (but not risperidone) enhances addiction\u2010related behaviors in mice: role of dopamine D2 receptors"],"prefix":"10.1111","volume":"14","author":[{"given":"Rita C.","family":"Carvalho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela F.","family":"Fukushiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Helfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Callegaro\u2010Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tha\u00eds F.","family":"Trombin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lineane H. F.","family":"Zanlorenci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leandro","family":"Sanday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina H.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Frussa\u2010Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,6,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00305-9"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(03)00231-5"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(87)91055-9"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2004.11.007"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00292-S"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00641-3"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00429212"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00492211"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.847477"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00824-9"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A053"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2008.04.001"},{"key":"e_1_2_6_14_1","first-page":"1497","volume-title":"Psychopharmacology: The Fourth Generation of Progress","author":"Casey DE","year":"1995"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300789"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.137.1.16"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.135.11.1409"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(95)02085-3"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01271-7"},{"key":"e_1_2_6_20_1","first-page":"12","article-title":"Behavioural sequelae of dopaminergic degeneration: postsynaptic supersensitivity?","volume":"11","author":"Creese I","year":"1975","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(98)00090-6"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.10-01-00303.1990"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90837-6"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn1579"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(83)90397-0"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2003.11.050"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2007.01.025"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2008.05.004"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(74)90078-2"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300949"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90429-L"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(76)90352-6"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(75)90233-4"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.130.1.82"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244649"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246489"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2003.12.018"},{"key":"e_1_2_6_38_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and 5HT2 pKi values","volume":"251","author":"Meltzer HY","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00429171"},{"key":"e_1_2_6_40_1","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1017\/S1092852900019842","article-title":"From clinical research to clinical practice: a 4\u2010year review of ziprasidone","volume":"10","author":"Nemeroff CB","year":"2005","journal-title":"CNS Spectr"},{"key":"e_1_2_6_41_1","first-page":"11","article-title":"Supersensitivity, drug withdrawal and open\u2010field behavior","volume":"18","author":"Palermo\u2010Neto J","year":"1982","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_6_42_1","first-page":"61","volume-title":"Dopaminergic Systems: Evolution from Biology to Clinical Aspects","author":"Palermo\u2010Neto J","year":"2001"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(03)00074-9"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(96)00448-0"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00421062"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200305000-00001"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2002000200013"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(97)00394-9"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-7634(01)00023-9"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0173(93)90013-P"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.95.8s2.19.x"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2001.9611038.x"},{"key":"e_1_2_6_53_1","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S0022-3565(25)13217-5","article-title":"5\u2010HT2 receptors blockade by ICI 169369 and other 5\u2010HT2 antagonist modulates the effects of D\u20102 dopamine receptor blockade","volume":"253","author":"Saller CF","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01188-8"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245606"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(76)90119-9"},{"issue":"10","key":"e_1_2_6_57_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852900025086","article-title":"Atypical antipsychotics: matching receptor profile to individual patient's clinical profile","volume":"9","author":"Shayegan DK","year":"2004","journal-title":"CNS Spectr"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674370204700710"},{"issue":"19","key":"e_1_2_6_59_1","first-page":"6","article-title":"The psychopharmacology of ziprasidone: receptor\u2010binding properties and real\u2010world psychiatric practice","volume":"64","author":"Stahl SM","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(97)00046-8"},{"key":"e_1_2_6_61_1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0022-3565(24)29589-6","article-title":"Long\u2010term effects of olanzapine, risperidone and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment","volume":"297","author":"Tarazi FI","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_62_1","first-page":"1100","article-title":"Olanzapine treatment for patients with schizophrenia and cocaine abuse","volume":"63","author":"Tsuang JW","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200212000-00017"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/10.5.488"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(99)00146-X"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.09.037"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(98)00042-3"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(95)00224-T"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1037\/0021-843X.97.2.118"},{"issue":"2","key":"e_1_2_6_70_1","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1523\/JNEUROSCI.14-03-01735.1994","article-title":"MK\u2010801 prevents alterations in the mesoaccumbens dopamine system associated with behavioral sensitization to amphetamine","volume":"14","author":"Wolf ME","year":"1994","journal-title":"J Neurosci"}],"container-title":["Addiction Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1369-1600.2008.00145.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1369-1600.2008.00145.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T02:05:08Z","timestamp":1738980308000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1369-1600.2008.00145.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,10]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1111\/j.1369-1600.2008.00145.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1369-1600.2008.00145.x","archive":["Portico"],"relation":{},"ISSN":["1355-6215","1369-1600"],"issn-type":[{"type":"print","value":"1355-6215"},{"type":"electronic","value":"1369-1600"}],"subject":[],"published":{"date-parts":[[2009,6,10]]},"assertion":[{"value":"2009-06-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}